Cargando…
Eculizumab use in patients with pneumococcal-associated hemolytic uremic syndrome and kidney outcomes
BACKGROUND: Streptococcus pneumoniae-associated hemolytic uremic syndrome (P-HUS) is a rare and severe disease. Only a few reports have been published about eculizumab use in P-HUS. METHODS: We analyzed demographic, clinical, and laboratory data of patients with P-HUS from our center. RESULTS: The c...
Autores principales: | Konopásek, Patrik, Zieg, Jakub |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584715/ https://www.ncbi.nlm.nih.gov/pubmed/37306721 http://dx.doi.org/10.1007/s00467-023-06037-2 |
Ejemplares similares
-
Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome
por: Vilalta, Ramon, et al.
Publicado: (2012) -
Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count
por: Dorresteijn, Eiske M., et al.
Publicado: (2012) -
COVID-19-associated atypical hemolytic uremic syndrome and use of Eculizumab therapy
por: Gill, Jasmeet, et al.
Publicado: (2021) -
Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome
por: Siedlecki, Andrew M., et al.
Publicado: (2018) -
Critical appraisal of eculizumab for atypical hemolytic uremic syndrome
por: Palma, Lilian M Pereira, et al.
Publicado: (2016)